Your browser doesn't support javascript.
The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19.
Focosi, Daniele; Tuccori, Marco; Franchini, Massimo.
  • Focosi D; North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.
  • Tuccori M; Division of Pharmacology and Pharmacovigilance, University of Pisa, 56126 Pisa, Italy.
  • Franchini M; Unit of Adverse Drug reaction Monitoring, Pisa University Hospital, 56124 Pisa, Italy.
Life (Basel) ; 11(2)2021 Feb 15.
Article in English | MEDLINE | ID: covidwho-1085058
ABSTRACT
Effective treatments specific for COVID-19 are still lacking. In the setting of passive immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of COVID-19 convalescent plasma (CCP) anti-SARS-CoV-2 Spike protein monoclonal antibodies (mAb), which have been granted emergency use authorization, have suggested benefit in early disease course (less than 72 hours from symptoms and seronegative). Meanwhile, polyclonal immunoglobulins (i.e., hyperimmune serum), derived either from CCP donations or from animals immunized with SARS-CoV-2 antigens, are likely to become the next nAb-derived candidate. We here discuss the pros and cons of hyperimmune serum versus CCP and mAb, and summarize the ongoing clinical trials of COVID-19 hyperimmune sera.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Year: 2021 Document Type: Article Affiliation country: Life11020144

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Year: 2021 Document Type: Article Affiliation country: Life11020144